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Background: The purpose of this study was to test the efficacy of cyclic Arg-Gly-Asp (RGD) 
peptide conjugated with polyionic complex nanomicelles as targeted therapy for glioma.
Methods: A stable cyclic RGD polyionic complex nanostructure, ie, a c(RGDfC) polyionic 
complex micelle, was synthesized and its biocompatibility with cultured neurons was assessed 
using a cell viability assay. Targeted binding to cultured glioma cells was evaluated by the 
CdTe quantum dot marking technique and a cell viability assay. The inhibitory effect of the 
nanomicelles against glioma cells was also evaluated, and their targeted migration into rat 
brain glioma cells and apoptotic effects were traced by the CdTe quantum dot marking and 
immunohistochemical staining.
Results: c(RGDfC) polyionic complex micelles did not affect the growth of neurons but 
bonded selectively to and inhibited proliferation of glioma cells in vitro. When tested in vivo, 
the micelles migrated into glioma cells, inducing apoptosis in the rat brain.
Conclusion: The c(RGDfC) polyionic complex micelle is an effective targeted therapy against 
glioma.
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Introduction
Glioma is one of the most common primary brain tumors, accounting for about 
30%–40% of all intracranial tumors.1 The annual incidence is growing gradually 
around the world, and has now increased to 2.4–7.0 per 100,000.1,2 Recurrence 
and mortality rates are still high, even though aggressive therapies have been used, 
including surgery, radiotherapy, and chemotherapy. The efficacy of antiglioma drugs 
is limited by their toxicity, as a result of their narrow therapeutic window, which 
affects therapeutic indices.
Short synthetic peptides containing the tripeptide sequence of Arg-Gly-Asp (RGD) 
are well known for their integrin-binding activity. RGD have been used recently for 
tumor-targeted imaging.3–6 This study was undertaken because, although RGD peptide-
conjugated nanomaterials are a research focus in the field of antitumor therapies,7 none 
of the relevant trials so far has resulted in an effective antiglioma drug.
A polyion complex micelle can be formed by electrostatic interaction in an aqueous 
medium. Polyion complexes have self-assembling core-shell structures which can 
protect a loaded drug from degradation by enzymes and engulfment by phagocytes. The 
polyion complex can extend the longevity of a drug in the blood, enhancing permeability 
and retention. Due to its proven biomedical compatibility, the polyion complex micelle 
is one of the most frequently used nanodelivery systems in biomedicine.8
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In this study, a polyion complex micelle was conjugated 
with an RGD-containing pentapeptide, ie, c(RGDfC, 
Cyclo(-Arg-Gly-Asp-D-Phe-Cys), forming an encapsulated 
poly-(aspartic acid) ion complex, ie, the c(RGDfC) polyionic 
complex micelle. Experiments were conducted to test 
the stability of the c(RGDfC) polyionic complex micelle 
against variations in pH and NaCl concentration, as well as 
its biocompatibility with neurons and its therapeutic effect 
against glioma cells. The targeting effect of c(RGDfC) 
polyion complex micelles was then evaluated by tracing 
them with CdTe quantum dots.
Materials and methods
Preparation of activated polyion 
complexes
Maleimide-polyethylene glycol (PEG)-g-N-diethanolamine 
(PDEA) and maleimide-PEG-g-poly(aspartamide) (PAsp) 
were gifted for this research by the Department of 
Macromolecular Science and the Key Laboratory of 
Macromolecular, Engineering of Polymers, Fudan University. 
First, 15.8 mg (5 mM) of maleimide-PEG-g-PDEA and 
13.8 mg (5 mM) of maleimide-PEG-g-PAsp were dissolved 
in 10 mL of 0.01 M phosphate-buffered saline (pH 7.4). The 
maleimide-PEG-g-PAsp solution was slowly dropped into 
the solution of maleimide-PEG-PDEA under gentle stirring. 
After 30 minutes, the solution was filtered using a 0.45 µm 
syringe-type filter before adding an appropriate amount 
of glutaraldehyde 2.5% solution (Shanghai Biochemical 
Reagent Company, Shanghai, China), stirring for 4 hours, and 
refiltering the entire solution again at 25°C. The final product 
was dried under vacuum for 8 hours. The zeta potential of 
the nanomicelles was determined using a Zetasizer Nano ZS 
(Malvern Instruments Ltd, Worcestershire, UK).
Preparation of RGD-conjugated polyion 
complexes
Because cyclic peptide pentapeptides reportedly had higher 
binding affinity and selectivity for integrin,9 c(RGDfC) was 
purchased from Shanghai Sangon Biological Engineering 
Technology and Services Company (Shanghai, China) for 
use in this work. c(RGDfC) was suggested with the polyion 
complex solution for 8 hours at 4°C. The molar ratio of 
c(RGDfC) to maleimide was 1:3, as indicated in a previous 
report.10 The reaction mixture was then added to a 1.5 × 20 cm 
Sepharose CL-4B column and eluted with 0.01 M phosphate-
buffered saline (pH 7.4). The turbid c(RGDfC) polyion 
complex fractions were visually identified and collected, 
and the polyion complex concentration was determined by 
turbidimetry using a UV2401 spectrophotometer at 350 nm 
(Shimadzu, Tokyo, Japan). The zeta potential was assessed 
using the Zetasizer Nano ZS.
Preparation of c(RGDfC) polyion 
complex micelles
A cosolvent evaporation method was used to prepare 
the c(RGDfC) polyionic complex micelles. First, 50 mg 
of c(RGDfC) polyionic complexes in 10 mL of acetone 
was added to phosphate-buffered saline (0.01 M, 50 mL, 
pH 7.4) in a dropwise manner. After 5 hours of stirring the 
solution at room temperature, a vacuum device was used 
to ensure complete removal of the organic solvent from 
the solution.
Transmission electron microscopy  
and dynamic light scattering
The morphology of the polyionic complex micelles was 
studied using a transmission electron microscope (Hitachi 
H-600, Tokyo, Japan, 250 kV). A drop of sample solution 
was allowed to settle on the copper grid for one minute. 
Excess solution was removed by wicking with filter paper 
for one minute. Dynamic light scattering measurements 
were performed on a Malvern Autosizer 4700, and the 
laser wavelength (λ) used for the measurements was 
514.5 nm.
Neuron culture
Wistar rats were purchased from the Experimental Animal 
Center of Shanghai Medical School, Fudan University, 
Shanghai. Primary neuron cultures were prepared from 
the brains of neonatal Wistar rats sacrificed at postnatal 
day 1, and cultured in Neurobasal®-A medium containing 
2% B27 supplement and glutamine 5 mmol/L (all from 
Gibco-BRL, Burlington, ON, Canada). The neonatal rats 
were decapitated and their heads rinsed in phosphate-buffered 
saline and glucose medium (7.9 mmol/L) solution containing 
penicillin 40,000 U/L and streptomycin 40,000 U/L (all from 
Gibco-BRL). The brain was rapidly removed from the skull, 
placed in phosphate-buffered saline and glucose medium, 
and dissected to remove the meninges. The hippocampi 
were placed in a tube containing 1 mL phosphate-buffered 
saline trypsin-DNase solution (1%, 0.1%, Gibco-BRL) 
for 15 minutes at room temperature. The forebrains were 
then rinsed three times with phosphate-buffered saline, 
and 1 mL Neurobasal-A medium was added. Mechanical 
dissociation machine was performed to obtain a monocell 
suspension, which was centrifuged using a Universal 16R 
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(Hettich, Beverly, MA) at 2000 rpm for 10 minutes at 4°C. 
The supernatant was removed and the pellet was resuspended 
in 5 mL Neurobasal-A and B27 glutamine medium. The 
cell number was then counted. Finally, the cells were plated 
onto 96-well plates (1 × 106 cells/mL) and polylysine-coated 
glass 6-well plates (1 × 106 cells/mL). The neuron cultures 
were kept for 7 days in a humidified incubator at 37°C and 
5% CO2, (CO2 incubator HERAcell 150, Thermo Electron 
Corporation, Waltham, MA). The culture medium was 
renewed every 3 days.
MTT assay for cell viability
For cell viability, 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyl-
tetrazolium bromide (MTT, Sinopharm Chemical Reagent 
Company, Shanghai, China), a yellow tetrazole assay, was 
performed following standard procedures for each well of 
cells post treatment. Briefly, cells cultured in 96-well plates 
were treated with 50 µL of MTT per well. After coculture, 
150 µL of dimethyl sulfoxide (Sinopharm Chemical Reagent 
Company) were added per well. After 20 minutes of reaction, 
the plate was subjected to ocular density (OD) detection using 
an enzyme-labeled meter (Multiskan 3, Thermo Electron 
Corporation) at a wave length of 550 nm. Cell viability was 
expressed as a percentage, and calculated using the following 
equation:
  CV (%) = (OD2/OD1) × 100%
where CV is cell viability, OD1 is the OD value before 
treatment, and OD2 is the OD value after treatment.
Human glioma cell culture
U87 human glioma and C6 rat glioma cell lines were gifted 
for this work by the Shanghai Cancer Institute. The glioma 
cells were plated into 96-well plates (1 × 104 cells/mL) and 
polylysine-coated glass 6-well plates (1 × 104 cells/mL), and 
grown in Dulbecco’s Modified Eagle’s Medium   (Gibco-BRL) 
with 20% fetal bovine serum in 5% CO2 at 37°C for 3 days. 
Culture medium was renewed every 3 days.
Preparation of quantum dot marked 
RGD-polyionic complex micelles
To trace the distribution of c(RGDfC) polyionic complex 
micelles, 0.5 mL of CdTe quantum dots (Quantum Dot 
Corporation, Hayward, CA) stabilized by thioglycolic acid 
was added to the copolymer solution. The resulting solu-
tion was precipitated repeatedly in ice-cold acetone, and 
the   precipitate was then washed three times with acetone to 
remove the unloaded CdTe quantum dots.
C6 cell-implanted animal model of glioma
C6 cell lines were maintained in Dulbecco’s Modified Eagle’s 
Medium, with 15% heat-inactivated fetal calf serum and 
glutamine 0.2 mM, neomycin 50 g/mL, and streptomycin 
100 µg/mL. An animal model of glioma was induced by 
stereotactic injection of C6 cells following a previously 
reported procedure,11 with minor modification. Briefly, 
C6 cells were harvested by trypsinization, pelleted by 
centrifugation, and resuspended for intracranial implantation. 
Anesthetized Wistar rats (n = 12 in each group) were placed 
in a stereotactic head frame, and a small right frontal 
craniectomy was drilled 2.5 mm from the midline and 1.0 mm 
anterior to bregma. C6 cells (1 × 106/10 µL) were implanted 
stereotactically to a depth of 4 mm below the craniectomy 
using a microinjection syringe. The craniectomy was resealed 
with bone wax and the scalp closed. For identification of 
tumor growth, contrast-enhanced computed tomography was 
conducted using a Somatom Emotion 16 device (Siemens, 
Shanghai, China) 3 weeks following implantation. All 
animal experiments were approved by the local animal 
care committee and were in accordance with international 
guidelines on the ethical use of animals.
Immunohistochemistry
On day 21 after glioma implantation, quantum dot-marked 
c(RGDfC) polyionic complex micelles or a control 
(phosphate-buffered saline) solution was injected into the 
rats via the tail vein. The rats were decapitated 24 hours 
later. Their brains were then fixed in 4% paraformaldehyde, 
frozen-sectioned into 10 µm slices, and stained with FITC-
conjugated anticaspase-3 antibody (500×; Chemicon, 
Shanghai, China) for marking of apoptotic cells, and 
Hoechst 33258 (200× , Sigma-Aldrich, Shanghai, China) for 
marking of cell nuclei, following standard procedures. The 
sections were then subjected to imaging under a fluorescent 
microscope.
Statistical analysis
The data are presented as the mean ± standard deviation. 
Statistical significance was determined using one-way analysis 
of variance followed by a post hoc test with statistical analysis 
software (SPSS 11.0, Lead Technologies, Chicago, IL).
Results
Micelle morphology
The c(RGDfC) polyionic complex micelles were successfully 
synthesized and their diameters [averaging 60.1 ± 9.2 nm 
(counts from 50 independent observations of micelle 
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diameters)] were homogeneous (Figure 1A). The c(RGDfC) 
polyionic complex micelles demonstrated different shapes. 
Most of them were dispersed, with rare exceptions, while 
several micelles aggregated with each other. This phenom-
enon might result from evaporation of the solvent on the 
transmission electron microscope grid.
Zeta potential of nanomicelles
The zeta potential of the c(RGDfC)-polyionic complex 
micelles is shown in Supplementary Figure 1. When 
0 , Z , 1, the zeta potential was negative. When Z = 1, 
the zeta potential was around zero. When Z . 1, the zeta 
potential turned positive. The zeta potential increased as 
a result of increasing PDEA concentration. (Z, Z = C1/C2; 
C1, concentration of PDEA; C2, concentration of PAsp).
Stability against pH variation and salinity
To quantify micellar stability against pH variation, dynamic 
light scattering was used to measure the relative light 
intensity of the c(RGDfC) polyionic complex micelles in 
solutions with different pH values. Because the micelles 
were administered intravenously, they would not encounter 
an acidic environment, so the pH was set at 6–10, covering 
the physiological pH range from 7.35 to 7.45. The dispersity 
of the c(RGDfC) polyionic complex micelles changed subtly 
with pH variation from 6.0 to 11.0 (Figure 1B). To quantify                 
micellar stability against salt, the micelles were exposed to 
different NaCl concentrations. Dispersity of the c(RGDfC) 
polyionic complex micelles was stable against a NaCl 
concentration range of 0–0.6 mol/L (Figure 1C).
Biocompatibility with neurons
To evaluate the biocompatibility of the c(RGDfC) polyionic 
complex micelles, 7-day primary cultured neurons in every 
well of 6-well dishes were treated with either c(RGDfC) 
polyionic complex micelles 150 µmol/mL or vehicle for 
24 hours. The neurons were stained with Hoechst 33258 
(a specific marker for the nucleus, 1:100, Invitrogen, 
Shanghai, China) and TUNEL (an apoptotic cell marker, 
1:200, Invitrogen). The stained neurons were then imaged 
under a fluorescent microscope. No significant differences 
were found between the apoptotic ratio of the control group 
(0.63% ± 0.07%, Figure 2A) and the group treated with 
c(RGDfC) polyionic complex micelles (0.75% ± 0.05%, 
Figure 2B). The apoptotic ratio was expressed as three 
independent counts of apoptotic cell number/total cell 
number under a 20 µm × 20 µm microscope.
To assess further the biocompatibility of the micelles 
with neurons, the MTT assay was used to determine cell 
viability. To perform a dose-dependent assay, 7-day primary 
neurons were pulsed with c(RGDfC) polyionic complex 
micelles, c(RGDfC), or polyionic complexes alone at four 
concentrations (0 µmol/mL, 50 µmol/mL, 150 µmol/mL, 
and 300 µmol/mL) for 24 hours. The pulsed neurons were 
then subjected to MTT assay (molarity refers to RGD). The 
MTT assay showed no significant reduction in cell viability 
in neurons treated with c(RGDfC) polyionic complexes, 
c(RGDfC), or polyionic complex micelles (Figure 2C).
To assess the time-dependent relationship between the 
following treatments and viability of neurons, 7-day primary 
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Figure 1 Morphological and physical features of c(RGDfC) polyionic complex micelles. 
(A)  Assemblies  of  c(RGDfC)  polyionic  complex  micelles  in  acetone/phosphate-
buffered saline (1:5) are shown in a dark-field transmission electron microscopic 
image (bar 200 nm). The c(RGDfC) polyionic complex micelles show homogeneity in 
size, with an average diameter of 60.1 ± 9.2 nm. (B) Stability of c(RGDfC) polyionic 
complex micelles against pH variation. The variations in relative light intensity with 
increasing pH for c(RGDfC) polyionic complex micelles were measured by dynamic 
light scattering. The total concentration for each micelle system was 0.5 mg/mL at a 
temperature of 25°C ± 0.1°C. Relative light intensity showed no abrupt change after 
pH treatment. (C) Stability of c(RGDfC) polyionic complex micelles against salt. The 
micelles were subjected to salt treatment at a series of NaCl concentrations of 0, 
0.05, 0.15, 0.3, 0.45, and 0.6 M. Relative light intensity was measured by dynamic light 
scattering (pH 7.4) to show dispersity. The relative light intensity showed no abrupt 
change after salt treatment. 
Abbreviation: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys).
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vehicle control group (0.77% ± 0.09%, Figure 3A) and 
that of the group that received polyionic complexes alone 
(0.80% ± 0.09%, Figure 3B, P . 0.05). However, significant 
differences were found between the vehicle control group and 
RGD alone group (98.19% ± 0.11%, Figure 3C, P , 0.001). 
Significant differences were also found between the vehicle 
control group and the group that received c(RGDfC) polyionic 
complex micelles (99.24% ± 0.13%, Figure 3D, P , 0.001). 
The apoptotic ratio was expressed as three independent 
counts of apoptotic cell number/total cell number under a 
20 µm × 20 µm microscope.
For cell viability, U87 cells were treated with c(RGDfC) 
polyionic complex micelles, c(RGDfC), or polyionic 
complexes at four concentrations, ie, 0 µmol/mL, 50 µmol/mL, 
150 µmol/mL, and 300 µmol/mL, and then subjected to 
MTT assay. Significant reductions in cell viability both in 
the c(RGDfC) polyionic complex-treated group and in the 
c(RGDfC)-treated group were observed (P , 0.05), while no 
significant reduction of cell viability was seen in the group 
treated with polyionic complex micelles (Figure 3E).
Preparation of quantum dot-marked 
RGD-polyionic complex micelles
To trace the distribution of c(RGDfC) polyionic complex 
micelles, the micelles were coated with CdTe quantum 
dots. The fluorescent shift from orange to reddish was due 
to electrostatic interaction between the carboxyl groups 
surrounding the quantum dots and active amine groups within 
the polyionic complex sphere (Figure 4). This demonstrated 
the effective combination and encapsulation of quantum dots 
within the polyionic complex.
Glioma inhibition in vivo
To determine whether the c(RGDfC) polyionic complex 
micelles could inhibit glioma cells in vivo, Wistar rats 
were implanted with the C6 glioma cell line and treated 
with c(RGDfC) polyionic complex micelles or vehicle. 
A mass with high density found within the contrast-enhanced 
computed tomographic image of the rat brain (Figure 5A) 
indicated successful implantation of glioma. c(RGDfC) 
polyionic complex micelles (300 µmol/mL, 1 mL per rat) 
were given to rats with glioma via the tail vein, setting 
phosphate-buffered saline (0.01 mol/L, 1 mL per rat) for rats 
with glioma and c(RGDfC) polyionic complex micelles for 
sham operation (stereotactic injection of Dulbecco’s Modified 
Eagle’s Medium without glioma cells) as controls. When the 
c(RGDfC) polyionic complex micelles were applied to rats 
with glioma, there was a statistically significant increase in 
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Figure 2 Biocompatibility of c(RGDfC) polyionic complex micelles with neurons. 
Neurons  stained  with  Hoechst  33258  for  nucleus  and  TUNEL  for  apoptosis 
after coculture with vehicle (A) or c(RGDfC) polyionic complex micelles (B) for 
24 hours (bar 40 µm). Seven-day primary cultured neurons in each well of 6-well 
dishes were treated with c(RGDfC) polyionic complex micelles (150 µmol/mL) for 
24 hours, stained with Hoechst 33258 and TUNEL and imaged under fluorescent 
microscope.  (C)  Cell  viability  of  neurons  following  dose-dependent  treatments 
determined by MTT assay. Seven-day primary neurons were given as 0, 50, 150, 
300 and µmol/mL c(RGDfC) polyionic complex micelles, c(RGDfC), or polyionic 
complexes,  respectively,  for  4  hours.  The  cells  were  subjected  to  MTT  assay 
following treatment. No significant reduction in cell viability was observed in the 
neurons with the c(RGDfC) polyionic complex, c(RGDfC), or polyionic complex 
micelles.  (D)  Viability  of  the  neurons  following  time-dependent  treatments 
determined by MTT assay. Neurons were cocultured with 150 µmol/mL c(RGDfC) 
polyionic complex, c(RGDfC), or polyionic complex micelles for a series of times, 
ie, 0, 2, 24, and 72 hours. The cells were subjected to MTT assay following treatment. 
No significant reduction of cell viability was observed in neurons treated with the 
c(RGDfC) polyionic complex, c(RGDfC), or polyionic complex micelles. 
Note: All cellular experiments were repeated at least three times as confirmation. 
Abbreviation: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys).
neurons were pulsed with c(RGDfC) polyionic complex 
micelles, c(RGDfC), or polyionic complexes in 300 µmol/mL 
for four durations (hours 0, 2, 24, and 72), respectively, 
and subjected to MTT assay. The MTT assay showed no 
significant reduction of viability in neurons treated with the 
c(RGDfC) polyionic complexes, c(RGDfC), or polyionic 
complex micelles (Figure 2D).
Inhibition of cultured U87 glioma cells
To investigate for possible inhibitory effects in vitro, U87 cells 
were treated with c(RGDfC) polyionic complex micelles 
(150 µmol/mL), polyionic complexes alone (150 µmol/mL), 
c(RGDfC) alone (150 µmol/mL), or vehicle for 4 hours and 
subjected to staining with antiglial fibrillary acid protein 
(red, 1:200, Invitrogen), a specific marker for astrocytes and 
TUNEL (green, 1:200, Invitrogen), an apoptotic cell marker 
and imaged under the fluorescent microscope. No significant 
differences were found between the apoptotic ratio of the 
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Figure 3 Inhibition of U87 glioma-derived cells after treatment with c(RGDfC) polyionic complex micelles. Apoptosis of U87 cells post treatment with c(RGDfC) polyionic 
complex micelles. Three-day U87 cells were treated with (A) phosphate-buffered saline, (B) 150 µmol/mL of polyionic complexes, (C) 150 µmol/mL of c(RGDfC), and 
(D) 150 µmol/mL of c(RGDfC) polyionic complex micelles for 4 hours and imaged under microscopy (bar 125 µm in each graph), and (E) viability of U87 cells post treatment, 
determined by MTT assay. To see whether the compound kills glioma cells, 3-day U87 cells cultured in 96-well plates were divided into 12 groups (n = 5), receiving 0, 50, 
150, 300 µmol/mL c(RGDfC) polyionic complex micelles, c(RGDfC), or polyionic complexes for 4 hours. 
Notes: The cells were subjected to MTT assay post treatment. Significant reduction of cell viability was observed in the group treated with c(RGDfC) polyionic complexes 
(#P , 0.05) and the group treated with c(RGDfC) (*P , 0.05), while no significant reduction of cell viability was seen in the group treated with polyionic complex micelles. 
All cellular experiments were repeated at least three times as confirmation. 
Abbreviation: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys).
median survival time (Figure 5B). Meanwhile, no deaths 
occurred in the sham operation group treated with c(RGDfC) 
polyionic complex micelles, indicating no significant toxicity 
of the micelles in vivo.
Target effect in vivo
To show whether the c(RGDfC) polyionic complex 
micelles could bind specifically to glioma cells in vivo, 
the rats were implanted with a C6 glioma cell line, treated 
with quantum dot-marked c(RGDfC) polyionic complex 
micelles, and subjected to standard immunohistochemical 
staining using caspase-3 (a specific marker for apoptotic 
cells) and Hoechst 33258 (a specific marker for cell nuclei). 
The cell density shown by Hoechst 33258 staining (blue) 
in the tumor area (Figure 6A) was much higher than that in 
the contralateral area (Figure 6B). The c(RGDfC) polyionic 
complex micelles traced by quantum dots (red) were found 
within the tumor area (Figure 6C), while little was found 
within the contralateral area (Figure 6D), indicating a 
glioma-targeted migration after administration. Apoptosis 
shown by caspase-3 staining (green) was found within the 
tumor area (Figure 6E) and sparing the contralateral area 
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(Figure 6F), indicating a glioma-selective apoptotic effect. 
By merging the above fluorescent images, apoptotic staining 
was found to overlap well with quantum dots, manifesting 
as yellow spots (Figure 6G). By contrast, this phenomenon 
was not found within the contralateral area (Figure 6H). 
Significant differences were found between the apoptotic 
ratio in the ipsilateral hemisphere (37.42% ± 0.31%) and 
that of the contralateral hemisphere (0.50% ± 0.12%, 
P , 0.001). The apoptotic ratio was expressed as three 
independent counts of (apoptotic cell number)/(total cell 
number) under a 5 µm × 5 µm microscope. Taken together, 
these data suggested that in vivo apoptosis of glioma cells 
was induced by the c(RGDfC) polyionic complex micelles 
that specifically.
Discussion
This study demonstrates the advantages of c(RGDfC) poly-
ionic complex micelles as a targeted therapy against glioma 
from three perspectives, ie, apoptotic potential, decreased 
cell viability when applied in vitro, and improved survival 
rate when used in vivo.
The findings from dynamic light scattering established 
the stability of the c(RGDfC) polyionic complex micelles 
against variation in pH and salt exposure. The viability of 
neurons was shown to be unaffected by c(RGDfC) polyionic 
complex micelles. This finding provides important evidence 
for the biocompatibility of a potential drug with activity 
against brain tumor cells. Biocompatibility was confirmed 
by the fact that the survival rate of rats was not affected by 
injection of c(RGDfC) polyionic complex micelles.
RGD is thought to induce apoptosis of tumor cells.12–14 
Cilengitide, a cyclic RGD peptide, has been used in clini-
cal trials for treatment of glioblastoma.15, However, RGD 
  peptide-conjugated nanomaterials were mainly used for imag-
ing rather than for treating tumors. RGD peptides can specifi-
cally recognize integrin, which is restrictively expressed on 
cell surfaces of malignant glioma cells.16 RGD peptide conju-
gated with nanomaterials enabled tracing of glioma in a pho-
toinduced electron transfer imaging system.17–19 We found that 
Figure 4 Quantum dot tracing of c(RGDfC) polyionic complex micelles. Quantum 
dot  marked  c(RGDfC)  polyionic  complex  micelles  in  a  cup.  (A)  Quantum  dot 
emitting orange fluorescence. (B) The fluorescent shift from orange to reddish due 
to the electrostatic interaction between carboxyl groups surrounding quantum dots 
and active amine groups within polyionic complex spheres (actual size). 
Note: This demonstrates the effective combination and encapsulation of quantum 
dots within a polyionic complex. 
Abbreviation: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys).
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Figure 5 Increased survival time by c(RGDfC) polyionic complex micelles in rat 
glioma. (A) Contrast-enhanced computer tomography of glioma in rat brain;10 µL 
medium containing 1 × 106 cells from a C6 malignant glioma cell line cells was 
directed into the caudate nucleus of the right brain of Wistar rats via stereotactic 
injection to establish an animal model of glioma. Enhanced computer tomography 
was  conducted  3  weeks  later  to  identify  the  existence  of  tumor  in  rat  brain. 
Because a brain image on computer tomography scan was known to be symmetric, 
a glioma in the right hemisphere could be recognized by comparison with the left 
hemisphere. Enhanced computer tomography signals (black arrows) were found 
within the hemisphere implanted with tumor cells (right). The number “7” was a 
sectional sequence mark. This figure is the 7th section (bar 3 mm). (B) On day 21, 
c(RGDfC) polyionic complex micelles (300 µmol/mL, 1 mL/rat) were given to the 
rats with glioma via their tail veins, setting the phosphate-buffered saline and sham 
operation as control. 
Note: Survival time was plotted and the statistical significance of median survival 
time was calculated (*P , 0.05). 
Abbreviations: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys); PBS, phosphate-
buffered saline.
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RGD and c(RGDfC) polyionic complex micelles, but not 
vehicle control or polyionic complexes, induced apoptosis 
of human glioma cells in vitro.
In vivo experiments demonstrated a statistically significant 
delay in death of rats with glioma treated with c(RGDfC) 
polyionic complex micelles, compared with those in the 
phosphate-buffered saline control and sham operation control 
groups. This phenomenon suggested an inhibitory effect of the 
c(RGDfC)-polyionic complex micelles on glioma cells. Immu-
nohistochemical staining combined with quantum dot tracing 
showed glioma-specific migration of the c(RGDfC) polyionic 
complex micelles after intravenous administration and specific 
apoptosis of the glioma cells. Most of the c(RGDfC) polyionic 
complex micelles-bond cells were apoptotic, while the other 
cells were not apoptotic. This indicates that c(RGDfC) polyionic 
complex micelles caused the apoptosis of the glioma cells.
The above evidence strongly supports a targeted thera-
peutic effect of c(RGDfC) polyionic complex micelles 
against human glioma cells. However, before possible clinical 
application of c(RGDfC) polyionic complex micelles, further 
investigations should include in vivo tests in an animal model 
of glioma. The concentration of micelles used in this study 
was quite high (ranging from 50 µmol/mL to 300 µmol/mL), 
which are most likely not to be reached in the brain tumors 
of patients if used systemically. Further, our experiments 
did not answer whether the micelles enter the brain through 
the blood–brain barrier or through craniectomy-induced 
lesions. In conclusion, we have pushed towards targeted 
therapy for human glioma by combining the carrier effects 
of nanoparticles with the targeting and apoptosis-inducing 
effects of RGD.
Conclusion
This study offers evidence that by conjugating a cyclic RGD 
peptide with polyionic complex micelles it is possible to 
achieve targeted therapy for glioma. However, there is still 
a long way to go from bench to bedside.
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Supplementary figure
Figure S1 Zeta potential of the c(RGDfC) polyionic complex micelle solution at pH 10. 
Notes: When 0 , Z , 1, the zeta potential was negative. When Z = 1, the zeta potential was around zero. When Z . 1, the zeta potential turned positive. The zeta potential 
increases as a result of increasing PDEA concentration. Z: Z = C1/C2. C1: concentration of PDEA, C2: concentration of PAsp. 
Abbreviations: c(RGDfC), Cyclo(-Arg-Gly-Asp-D-Phe-Cys); PDEA, N-diethanolamine; PAsp, poly(aspartamide).
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